Advertisement

Topics

Phase 3 ARCHES trial evaluating Xtandi plus ADT in men with mHSPC meets primary endpoint

08:05 EST 24 Dec 2018 | PharmaBiz

Astellas Pharma Inc. and Pfizer Inc. announced that the phase 3 ARCHES trial evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone─sensitive prostate cancer

Original Article: Phase 3 ARCHES trial evaluating Xtandi plus ADT in men with mHSPC meets primary endpoint

NEXT ARTICLE

More From BioPortfolio on "Phase 3 ARCHES trial evaluating Xtandi plus ADT in men with mHSPC meets primary endpoint"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Endocrinology
Diabetes Diabetes Endocrine Disorders Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several g...